Glaxo Wellcome set to pass the acid test
Article Abstract:
Glaxo Wellcome should benefit from a settlement in a court case involving Zantac in the US. The acquisition of Wellcome by Glaxo brings clear benefits such as an expansion of Glaxo's sales base, and cost reductions which should help boost earnings. A boost has been given to the drugs pipeline from projects such as LTC, an Aids treatment. Approval for 3TC in the US should help boost Retrovir sales, since a combination of drugs appears to be more effective. Debt was increased by the takeover, but the debt level should fall.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Oxford Molecular: byte-sized doses
Article Abstract:
Oxford Molecular supplies pharmaceutical concerns with software for developing new drugs. The company aims to develop a standard product for the industry. Pharmaceutical companies face increased costs and are seeking ways of developing drugs more rapidly and more cheaply. The company carries out research consultancy work and supplies drug design ideas to large pharmaceutical concerns, in addition to writing software which it installs and maintains.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Biofocus
Article Abstract:
The performance of Biofocus is examined in detail. The company operates in a market that is growing, and its management is experienced, though stock liquidity is poor.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic: